Capricor Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $105.82 million
- Book Value:
- Revenue TTM:
- $2.55 million
- Operating Margin TTM:
- Gross Profit TTM:
- $1.75 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Capricor Therapeutics Inc had its IPO on 2007-02-13 under the ticker symbol CAPR.
The company operates in the Healthcare sector and Biotechnology industry. Capricor Therapeutics Inc has a staff strength of 74 employees.
Shares of Capricor Therapeutics Inc opened at $4.13 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $4.06 - $4.27, and closed at $4.12.
This is a -1.67% slip from the previous day's closing price.
A total volume of 83,257 shares were traded at the close of the day’s session.
In the last one week, shares of Capricor Therapeutics Inc have slipped by -9.65%.
Capricor Therapeutics Inc's Key Ratios
Capricor Therapeutics Inc has a market cap of $105.82 million, indicating a price to book ratio of 6.4959 and a price to sales ratio of 61.6934.
In the last 12-months Capricor Therapeutics Inc’s revenue was $2.55 million with a gross profit of $1.75 million and an EBITDA of $-29164252. The EBITDA ratio measures Capricor Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Capricor Therapeutics Inc’s operating margin was -1163.93% while its return on assets stood at -40.6% with a return of equity of -134.49%.
In Q4, Capricor Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Capricor Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.09 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Capricor Therapeutics Inc’s profitability.
Capricor Therapeutics Inc stock is trading at a EV to sales ratio of 35.4213 and a EV to EBITDA ratio of -2.0433. Its price to sales ratio in the trailing 12-months stood at 61.6934.
Capricor Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $50.09 million
- Total Liabilities
- $23.59 million
- Operating Cash Flow
- Capital Expenditure
- $1.10 million
- Dividend Payout Ratio
Capricor Therapeutics Inc ended 2023 with $50.09 million in total assets and $0 in total liabilities. Its intangible assets were valued at $50.09 million while shareholder equity stood at $11.79 million.
Capricor Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $23.59 million in other current liabilities, 25241.00 in common stock, $-137079811.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.60 million and cash and short-term investments were $41.42 million. The company’s total short-term debt was $682,039 while long-term debt stood at $3.38 million.
Capricor Therapeutics Inc’s total current assets stands at $42.89 million while long-term investments were $0 and short-term investments were $31.82 million. Its net receivables were $547580.00 compared to accounts payable of $4.83 million and inventory worth $0.
In 2023, Capricor Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $1.10 million.
Comparatively, Capricor Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Capricor Therapeutics Inc stock is currently trading at $4.12 per share. It touched a 52-week high of $6.58 and a 52-week low of $6.58. Analysts tracking the stock have a 12-month average target price of $15.
Its 50-day moving average was $4.37 and 200-day moving average was $4.7 The short ratio stood at 4.2 indicating a short percent outstanding of 0%.
Around 264.3% of the company’s stock are held by insiders while 1092% are held by institutions.
Frequently Asked Questions About Capricor Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.